Skip to main content

Table 1 Baseline characteristics of the study sample

From: Associations between comorbidities, their treatment and survival in patients with interstitial lung diseases – a claims data analysis

Study sample

N

36,817

%

 Idiopathic interstitial pneumonias (IIP)

14,453

39.3

 Other fibrosing ILDs (OFI)

7187

19.5

 Sarcoidosis (SARC)

9106

24.7

 Drug-associated ILDs (DAI)

407

1.1

 Pneumoconiosis (PNE)

1579

4.3

 Radiation-associated pneumonitis (RAP)

464

1.3

 Eosinophilic pneumonia (EPP)

1518

4.1

 Hypersensitivity pneumonitis (HP)

967

2.6

 Connective tissue disease-associated ILD (CTD)

1140

3.1

Ø age (years) at diagnosis (SD)

66.0

14.6

Male gender

20,704

56.2

Ø survival in months (SD)

29.6

0.31

Dead at end of observation period

11,422

31.0

Median number of comorbidities (IQR)a

5.0

[3.7]

Non-ILD-related hospitalization (%) during observation

24,665

67.0

ILD-related hospitalization (%) during observation

3304

9.0

  1. All figures as N (%) unless reported otherwise
  2. IQR, interquartile range, SD standard deviation
  3. a31 comorbid conditions from the Elixhauser Index amended by PH, lung cancer, GERD, IHD, thrombosis, and OSAS yields a maximum of 37